Buysiders think biotech is poised - and now financed - for future growth even if markets take a brief pause at some point this quarter. Generalist investors are at long last helping to fuel demand for new biotech issuances, including an expansion of the first legitimate IPO window in a decade.

On June 18, IPOs in aggregate crossed the $1 billion threshold with 19 deals sold over 4.7 months. The year to date total now stands at 25, with at least 13 companies still in the queue (see "IPO Queue," A2).